Background We conducted a multinational, randomized study to compare radiotherapy alone
with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal growth …

Background Previous results from our phase 3 randomised trial showed that adding
cetuximab to primary radiotherapy increased overall survival in patients with locoregionally …

Background A randomized phase 3 trial of the treatment of squamous-cell carcinoma of the
head and neck compared induction chemotherapy with docetaxel plus cisplatin and …

Checkpoint inhibitors have revolutionized cancer treatment. However, only a minority of
patients respond to these immunotherapies. Here, we report that blocking the inhibitory NKG2A …

Purpose Patients with advanced, incurable thyroid cancer not amenable to surgery or
radioactive iodine (131 I) therapy have few satisfactory therapeutic options. This multi-institutional …

PURPOSE Biomarkers that can predict response to anti–programmed cell death 1 (PD-1)
therapy across multiple tumor types include a T-cell–inflamed gene-expression profile (GEP), …

… MTD in part A was 200 mg bid, but this dose was discontinued in part B because of
toxicity. The 50% MTD (100 mg bid) was well tolerated. Rash was the most frequent and …

Purpose To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics (PKs),
pharmacodynamics, and preliminary anticancer activity of ramucirumab (IMC-1121B), a fully …

Purpose XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth
factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive …

Purpose To establish the safety profile and antitumor activity of the anti–programmed death
1 receptor monoclonal antibody, pembrolizumab, in patients with recurrent or metastatic …